Stoxline.com

Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Otonomy, Inc. (OTIC)

0.1054   -0 (-0.09%) 03-17 15:59
Open: 0.1056 Pre. Close: 0.1055
High: 0.1072 Low: 0.1053
Volume: 239,663 Market Cap: 7(M)

Technical analysis

as of: 2023-03-20 9:18:34 AM
Overall:       
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Target: Six months: 0.13     One year: 0.15
Support: Support1: 0.1    Support2: 0.09
Resistance: Resistance1: 0.11    Resistance2: 0.13
Pivot: 0.1
Moving Average: MA(5): 0.1     MA(20): 0.1
MA(100): 0.1     MA(250): 0.87
MACD: MACD(12,26): -0.1     Signal(9): 0
Stochastic oscillator: %K(14,3): 44.7     %D(3): 49.8
RSI: RSI(14): 47.2
52-week: High: 2.53  Low: 0.05
Average Vol(K): 3-Month: 2,117 (K)  10-Days: 443 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ OTIC ] has closed above bottom band by 23.7%. Bollinger Bands are 92.9% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 144 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 0.11 - 0.11 0.11 - 0.11
Low: 0.1 - 0.1 0.1 - 0.1
Close: 0.1 - 0.11 0.11 - 0.11

Company Description

Otonomy, Inc., a biopharmaceutical company, develops therapeutics for neurotology in the United States. The company offers OTO-313, a sustained-exposure formulation of N-methyl-D-aspartate receptor antagonist gacyclidine, which is in Phase II clinical trials to treat tinnitus; and OTO-413, a sustained-exposure formulation of brain-derived neurotrophic factor that is in Phase IIa clinical trials for the repair of cochlear synaptopathy and the treatment of speech-in-noise hearing difficulties. It also develops OTO-510, an otoprotectant for the prevention of cisplatin-induced hearing loss; OTO-825, a gene therapy for the treatment of congenital hearing loss; and OTO-6XX induces hair cell repair and regeneration for the treatment of severe hearing loss. The company has license agreements with University of California and DURECT Corporation; and strategic collaboration with Applied Genetic Technologies Corporation to develop and commercialize gene therapy for congenital hearing loss. Otonomy, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Headline News

Mon, 20 Mar 2023
North American Morning Briefing: Banking Sector -2- - Marketscreener.com

Mon, 13 Mar 2023
North American Morning Briefing : Investors Digest -3- - Marketscreener.com

Mon, 06 Mar 2023
North American Morning Briefing : Focus This Week -3- - Marketscreener.com

Wed, 28 Dec 2022
Nasdaq delists securities of Tuscan Holdings, Clovis Oncology ... - Seeking Alpha

Wed, 28 Dec 2022
Elk Capital Makes Investment in Otonomy - Nasdaq

Mon, 19 Dec 2022
Otonomy Provides Corporate Update - GlobeNewswire

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Neutral
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Outperform
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 57 (M)
Shares Float 48 (M)
% Held by Insiders 10.2 (%)
% Held by Institutions 35.8 (%)
Shares Short 1,420 (K)
Shares Short P.Month 257 (K)

Stock Financials

EPS -1.1
EPS Est Next Qtl -0.69
EPS Est This Year -3.24
EPS Est Next Year -2.31
Book Value (p.s.) 1.37
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -38.2
Return on Equity (ttm) -118.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) -0.01
Sales Per Share 0
EBITDA (p.s.) -0.86
Qtrly Earnings Growth 0
Operating Cash Flow -47 (M)
Levered Free Cash Flow -27 (M)

Stock Valuations

PE Ratio -0.1
PEG Ratio -0.1
Price to Book value 0.07
Price to Sales 0
Price to Cash Flow -0.13

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
android_stock_chart
StockChart iOS
stoxline_lite
StoxlineLite iOS
stoxline_pro
StoxlineLite iOS
Option_Calculator
OptionCalc iOS
android_stock_chart
StockChart Android
stoxline_lite
StoxlineLite Android
stoxline_pro
StoxlinePro Android
Option_Calculator
OptionCalc Android
(c) 2006-2022 Stoxline.com | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.